New oral antithrombotics: a need for laboratory monitoring. For.
Mismetti
P
P
University Jean Monnet of Saint-Etienne, EA3065, F-42023, Saint-Etienne, France. patrick.mismetti@chu-st-etienne.fr
Laporte
S
S
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D016903:Drug Monitoring / Q000379:methods*; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors; D014859:Warfarin / Q000008:administration & dosage
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014812:Vitamin K; D014859:Warfarin; D006493:Heparin